Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
11/17/2016
|
APRI |
|
NDA Submission |
Other |
None |
|
11/30/2016
|
LXRX |
|
510K Submission |
Oncology |
Orphan Drug, Priority Review |
|
12/11/2016
|
SPPI |
|
PDUFA |
Oncology |
None |
|
12/11/2016
|
SPPI |
|
PDUFA |
Oncology |
Fast Track |
|
12/15/2016
|
DVAX |
|
PDUFA |
Infectious Disease |
None |
|
12/28/2016
|
CEMP |
|
PDUFA |
Other |
Fast Track |
|
12/28/2016
|
AAAP |
|
PDUFA |
Oncology |
Fast Track, Orphan Drug, Priority Review |
|
H2 2016
|
CRMD |
|
Phase 3 Results |
Other |
Fast Track |
|
Q4 2016
|
GWPH |
|
NDA Submission |
Neurology |
Fast Track, Orphan Drug |
|
Q4 2017
|
MRUS |
|
Phase 1/2 Results |
Oncology |
None |
|